MERLIN

What MERLIN does

MERLIN Gesellschaft fuer mikrobiologische Diagnostika mbH is a microbiology diagnostics company headquartered in Bornheim, Germany, founded in 1990 and operating as a wholly-owned subsidiary of Bruker Corporation since 2017. The company develops and manufactures broth microdilution (BMD)-based antimicrobial susceptibility testing (AST) and antifungal susceptibility testing (AFST) products under the MICRONAUT and UMIC brands. Its products are designed for clinical microbiology laboratories, veterinary diagnostic laboratories, and antibiotic stewardship teams working across human and animal health. Customers engage through dedicated microbiology channels at Bruker ([email protected]) and the legacy Merlin address ([email protected]), with the Bruker Microbiology & Diagnostics unit providing global distribution, applications support, and service infrastructure.

The MICRONAUT line is a panel-based BMD portfolio addressing specialty and routine AST/AFST workflows. MICRONAUT-S is positioned as the only BMD system differentiating all Ambler classes of ß-Lactamases, serving carbapenem-resistance screening. MICRONAUT-AM provides EUCAST-compliant antifungal susceptibility testing. MICRONAUT-VET extends the BMD platform into veterinary susceptibility testing. The UMIC line consists of ready-to-use, single-drug BMD strips for critical and last-resort antibiotics — including Colistin, Piperacillin-Tazobactam, Vancomycin-Teicoplanin, Daptomycin, Linezolid, Cefiderocol — plus antifungal strips (Amphotericin B, Fluconazole, Voriconazole). All products are formulated to ISO 20776-1 reference standards and aligned with EUCAST and CLSI breakpoints, which are mandatory specifications for clinical AST reporting.

The business operates as a specialty consumables manufacturer within Bruker's Microbiology & Diagnostics segment, generating revenue through panel and strip sales distributed globally via Bruker's commercial footprint. With 11-50 employees, MERLIN functions as a focused product line / R&D entity within a larger parent, leveraging Bruker's regulatory, logistics, and customer-service scale rather than maintaining an independent salesforce. (Note: aggregated input also contained material referencing a U.S. aerospace company trading on Nasdaq under "MRLN"; this data has been treated as unrelated and excluded from the analysis, as firmographic attributes — Bornheim, Germany; founded 1990; merlin-diagnostika.de; microbiological diagnostics — clearly identify the subject as MERLIN Gesellschaft.)

Name

MERLIN

Legal name

Merlin, Inc.

Website

https://merlin-diagnostika.de

Company type

Public

Founded year

1990

Operating status

Ipo

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical Microbiology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industry

Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology) (HLAMADAC)

Keywords

• Antimicrobial susceptibility testing
• Broth microdilution diagnostics
• MIC determination products
• Clinical microbiology testing
• Antifungal susceptibility testing

Headquarters

HQ city

Bornheim

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Distribution channels1 record

Core offering

MERLIN develops and manufactures the MICRONAUT broth microdilution (BMD) product portfolio and UMIC ready-to-use unitary MIC testing strips for antimicrobial and antifungal susceptibility testing. The products deliver true Minimum Inhibitory Concentration (MIC) values based on the worldwide accepted BMD reference method, with EUCAST and CLSI compliance for routine and specialty clinical microbiology and veterinary laboratories.

Product overview

Merlin, Inc. is an aerospace and defense technology company that has developed the Merlin Pilot, an autonomous flight system combining AI and hardware for scalable, certifiable solutions. The company operates a dual military-commercial strategy as a key differentiator. The available source material does not contain detailed product portfolio information beyond the core autonomous flight system offering.

Differentiator

Problem solved

Functional benefit

Products and services

• MICRONAUT Product Portfolio Broad range of specialty and routine antimicrobial susceptibility testing solutions based on the worldwide accepted broth microdilution reference method, delivering true MIC results of highest accuracy, serving clinical microbiology and veterinary laboratories.
• UMIC Ready-to-use unitary MIC testing strips with 12 wells each containing dried antibiotics, prepared according to ISO 20776-1 standard, providing flexibility to test one or several drugs for a clinical isolate from the same bacterial inoculum. Available for critically important antibiotics including Colistin, Piperacillin-Tazobactam, Vancomycin-Teicoplanin, Daptomycin, Linezolid, and Cefiderocol.
• MICRONAUT-AM Antifungal susceptibility testing (AFST) plates for automated or manual susceptibility testing of yeast and cryptococci according to the latest EUCAST standards, addressing the need for standardized routine AFST in the microbiology lab.
• MICRONAUT-S Anaerobes MIC AST plate based on the broth microdilution (BMD) procedure providing phenotypic detection of clinically relevant resistance mechanisms in anaerobic pathogens such as Clostridium spp., Bacteroides spp., and Peptostreptococcus spp.
• MICRONAUT-S MDR MRGN-Screening AST plate based on the standard broth microdilution (BMD) procedure for the phenotypic detection of clinically relevant resistance mechanisms, including confirmation of cephalosporinases and carbapenemases in Enterobacterales and non-fermenters.
• MICRONAUT-S MRSA/GP System based on the broth microdilution (BMD) procedure for the phenotypic detection of clinically relevant single or multi-resistance in staphylococci, enterococci, and streptococci organisms, with susceptibility testing for highly effective backup antibiotics including ceftaroline, linezolid, tigecycline, daptomycin, and vancomycin.
• MICRONAUT-S ß-Lactamases Detection Detection system based on broth microdilution that can differentiate between all Ambler class A (ESBL, KPC), class B (MBL), class C (AMP-C), and class D (OXA-48-like) cephalosporinases and/or carbapenemases.
• MICRONAUT-IVD System Range of antibiotic resistance and specialty susceptibility testing solutions offered under the MICRONAUT-IVD system brand, providing flexibility and automation options for routine and advanced AST workflows.
• MICRONAUT-VET Veterinary-specific product line delivering species-specific true MIC values for a broad spectrum of veterinary-specific antibiotics based on the broth microdilution reference procedure, serving veterinary microbiology laboratories.

Quantifiable outcome

• True MIC values for accurate antimicrobial susceptibility testing
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• BrukercoreOthers · 1 January 2017MERLIN Gesellschaft fuer mikrobiologische Diagnostika mbH is a Bruker company since 2017. Development and manufacturing of MICRONAUT and UMIC products is done by MERLIN as a wholly-owned subsidiary of Bruker.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• bioMérieux: Global leader in clinical microbiology diagnostics offering Vitek 2 for automated AST and ETEST gradient strips. Directly competes with MERLIN in the antimicrobial/antifungal susceptibility testing category serving the same clinical microbiology lab customers.
• Thermo Fisher Scientific: Markets the Sensititre product line, which uses broth microdilution (BMD) reference methodology for AST — the same core technology underpinning MICRONAUT. A direct competitor for BMD-based specialty AST in clinical microbiology labs.
• Beckman Coulter (Danaher): Provides the MicroScan system for automated identification and antimicrobial susceptibility testing in clinical microbiology laboratories. Competes head-to-head with MERLIN's MICRONAUT/UMIC for AST workflow share.
• BD (Becton Dickinson): BD Phoenix is a widely deployed automated AST/ID system used in clinical microbiology labs alongside BD MAX molecular platforms. Serves the same hospital microbiology customer base, directly competing for AST share of wallet.
• Liofilchem: Italian IVD manufacturer producing MIC test strips, BMD-based susceptibility testing panels, and a broad microbiology consumables catalog. A direct specialist competitor to MERLIN for AST strips and BMD reagents.
• ELITechGroup: European IVD company offering clinical microbiology and susceptibility testing reagents, including ATB strips for bacteria and yeasts. Overlaps with MERLIN's MICRONAUT product portfolio for clinical AST/AFST.

Broad incumbents

• Bio-Rad Laboratories: Broad life science tools and diagnostics company with microbiology and clinical diagnostics product lines. While not AST-specialized, it overlaps with MERLIN's lab customer base across QC and clinical microbiology workstreams.
• Bruker Corporation: Parent company of MERLIN since 2017 and owner of the MICRONAUT/UMIC manufacturing operation. Operates a broader microbiology and diagnostics portfolio (including MALDI Biotyper, IR Biotyper) that subsumes MERLIN's specialty BMD products.
• QuidelOrtho: Broad infectious disease diagnostics player with microbiology and rapid testing products serving hospital and reference labs. Competes indirectly with MERLIN by capturing antibiotic decision-support and resistance-detection workflow budgets.

Emerging players

• Copan Diagnostics: Specializes in microbiology sample collection, transport, and pre-analytic automation (e.g., WASP, WASPLab). Adjacent to MERLIN's downstream AST step, serving the same clinical lab workflow upstream and enabling ecosystem-level partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/MERLIN.Diagnostika
• LinkedInlinkedin.com/company/merlin-diagnostika-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MERLIN